Skip to main content
Fig. 4 | Journal of Experimental & Clinical Cancer Research

Fig. 4

From: A subset of diffuse-type gastric cancer is susceptible to mTOR inhibitors and checkpoint inhibitors

Fig. 4

Phosphorylated mTOR expression is a prognostic marker for diffuse-type GC patients, and Wnt-mTOR axis is involved in the growth regulation of diffuse-type GC-initiating cells. a, c Representative immunohistochemical micrographs of phosphorylated mTOR expressions in primary intestinal-type (a) and diffuse-type (c) GC tissues. b, d Kaplan-Meier analyses of overall survival for non-diffuse-type (b) and diffuse-type (d) GC patients with phosphorylated mTOR expression. Diffuse-type GC patients with strong phosphorylated mTOR expression (solid red line) had a significant poorer outcome than those with weak phosphorylated mTOR expression (dotted blue line) (P = 0.044), while no significant differences were found between the two in non-diffuse type GC patients. e Wnt-mTOR axis is involved in the growth regulation of diffuse-type GC-initiating cells. Results on effects of temsirolimus, Wnt3a, R-spondin-1, CHIR99021, and FH535 on the growth of diffuse- and intestinal-type GC-initiating cells in primary culture, shown in Additional file 1: Figure S9, and Figures S11 to S14 are summarized. Significant growth stimulation is shown by upward arrows, while significant growth suppression by downward arrows, respectively (no significant changes by horizontal arrows). Strong (more than 151%) growth stimulations are shown by purple, and strong (less than 66%) and weak (67–100%) growth suppressions are shown by blue and light blue, respectively (no significant changes by light gray)

Back to article page